TAILIEUCHUNG - TYPE 2 DIABETES - National clinical guideline for management in primary and secondary care (update)

The evidence base for the insulin secretagogues was more extensive than ascertained for the parent guideline. However, in many of the papers in which they are compared to other drugs they were being used as the comparator therapy rather than the investigated therapy. New evidence did not lead to new conclusions about the role of these drugs in clinical management, either from the point of view of efficacy or safety. Sulfonylureas proved as efficacious as newer comparator therapies in reducing surrogate outcomes (principally HbA1c) highlighting that they still have a role in modern management of Type 2 diabetes. In the ADOPT study54 the sulfonylurea glibenclamide controlled HbA1c. | The National Collaborating Centre for Chronic Conditions Funded to produce guidelines for the NHS by NICE TYPE 2 DIABETES National clinical guideline for management in primary and secondary care update This is an update of the following NICE inherited clinical guidelines on Type 2 diabetes which were published in 2002 E - retinopathy F - renal disease G - blood glucose H - management of blood pressure and blood lipids The recommendations on thiazolidinediones R40 to R43 chapter 10 GLP-1 mimetic exenatide R44 to R46 chapter 10 and insulin therapy R49 to R55 chapter 11 have been updated and replaced by NICE short clinical guideline 87 Type 2 diabetes newer agents for blood glucose control in type 2 diabetes available at CG87shortguideline . This short guideline contains details of the methods and evidence used to develop the updated recommendations. Chapters 10 and 11 should be read in conjunction with the short guideline. Published by Royal College of Physicians Setting higher medical standards Royal College of Physicians The Royal College of Physicians plays a leading role in the delivery of high-quality patient care by setting standards of medical practice and promoting clinical excellence. We provide physicians in the United Kingdom and overseas with education training and support throughout their careers. As an independent body representing over 20 000 Fellows and Members worldwide we advise and work with government the public patients and other professions to improve health and healthcare. National Collaborating Centre for Chronic Conditions The National Collaborating Centre for Chronic Conditions NCC-CC is a collaborative multiprofessional centre undertaking commissions to develop clinical guidance for the National Health Service NHS in England and Wales. The NCC-CC was established in 2001. It is an independent body housed within the Clinical Standards Department at the Royal College of Physicians of London. The NCC-CC is funded by the National

• Y học thường thức
• certifying energy
• energy efficient buildings
• Pediatric Infectious
• Fungal Infections
• Patients of Paediatric Age
• Infantile Chronic